Follicular Lymphoma
📧 Sign up to get email alerts when something new happens for Follicular Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2013-12-04Clinical Trial Update: Efficacy and Safety Study of Oral Fludarabine Phosphate in Combination With Mitoxantrone as First Line Treatment in Follicular NHL [Phase 2]
Phase 2 study evaluating the efficacy and safety of combining oral fludarabine phosphate with mitoxantrone as first-line therapy for follicu…
-
CLINICAL_TRIALS trial_result · 2013-09-30Clinical Trial Update: 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma [Phase 1]
Phase 1 trial evaluating Triapine (3-AP) in combination with gemcitabine in patients with advanced solid tumors or lymphoma has completed. I…
-
CLINICAL_TRIALS trial_result · 2013-09-30Clinical Trial Update: Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia [Phase 1]
Phase 1 trial evaluating bortezomib and fludarabine with or without rituximab in relapsed or refractory indolent non-Hodgkin lymphoma or chr…
-
CLINICAL_TRIALS trial_result · 2013-08-26Clinical Trial Update: Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 trial evaluating rituximab with interleukin-12 in several B-cell non-Hodgkin lymphomas. The study status is completed.
-
CLINICAL_TRIALS trial_result · 2013-07-01Clinical Trial Update: FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma [Phase 2]
A terminated Phase 2 trial evaluated FR901228 alone or with Rituximab and Fludarabine in relapsed or refractory low-grade B-cell non-Hodgkin…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2013-06-06Clinical Trial Update: Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer [Phase 1]
Phase 1 trial evaluating rituximab in combination with interleukin-2 in various hematologic cancers has completed.
-
CLINICAL_TRIALS trial_result · 2013-06-04Clinical Trial Update: Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma [Phase 1]
Phase 1 study evaluating a combination of alvocidib, fludarabine phosphate, and rituximab in various B-cell lymphoproliferative disorders, w…
-
CLINICAL_TRIALS trial_result · 2013-06-04Clinical Trial Update: 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer [Phase 1]
Phase 1 clinical trial evaluating the combination of tanespimycin (17-allylamino-17-demethoxygeldanamycin) and bortezomib in relapsed or ref…
-
CLINICAL_TRIALS trial_result · 2013-05-16Clinical Trial Update: Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction [Phase 1]
This Phase 1 trial evaluated bortezomib in patients with advanced cancer and kidney dysfunction. The study has completed.
-
CLINICAL_TRIALS trial_result · 2013-05-16Clinical Trial Update: PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma [Phase 1]
A Phase 1 trial evaluating PXD101 in combination with 17-N-allylamino-17-demethoxygeldanamycin for metastatic or unresectable solid tumors o…
-
CLINICAL_TRIALS trial_result · 2013-05-03Clinical Trial Update: PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas [Phase 1]
A Phase 1 study evaluating belinostat (PXD101) in combination with bortezomib in adults with advanced solid tumors or lymphomas has complete…
-
CLINICAL_TRIALS trial_result · 2013-04-29Clinical Trial Update: Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma [Phase 2]
A Phase 2 study evaluated Velcade (bortezomib) in patients with relapsed follicular lymphoma; the trial completed and results were posted in…
-
CLINICAL_TRIALS trial_result · 2013-04-12Clinical Trial Update: VELCADE® Plus Rituximab in Non Hodgkin's Follicular Lymphoma [Phase 2]
Phase 2 trial of Velcade (bortezomib) plus Rituximab for follicular non-Hodgkin lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2013-02-28Clinical Trial Update: Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma [Phase 3]
A Phase 3 trial evaluating interleukin-2 versus observation after standard therapy in adults with recurrent non-Hodgkin lymphoma has complet…
-
CLINICAL_TRIALS trial_result · 2013-02-27Clinical Trial Update: Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's Lymphoma [Phase 3]
Phase 3 trial evaluating chemotherapy with or without monoclonal antibody therapy for stage III or stage IV low-grade follicular lymphoma ha…
-
CLINICAL_TRIALS trial_result · 2013-02-21Clinical Trial Update: Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL [NA]
The study evaluated a Rituximab, Cyclophosphamide, Bortezomib, and Prednisone regimen in patients with stage III/IV follicular lymphoma or m…
-
CLINICAL_TRIALS trial_result · 2013-02-01Clinical Trial Update: Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia [NA]
A clinical trial evaluated arsenic trioxide in patients with relapsed or refractory lymphoma and leukemia; the study status is terminated.
-
CLINICAL_TRIALS trial_result · 2013-01-25Clinical Trial Update: 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas [Phase 1]
Phase 1 clinical trial evaluating 17-DMAG (alvespimycin), an HSP90 inhibitor, in patients with metastatic or unresectable solid tumors or ly…
-
CLINICAL_TRIALS trial_result · 2013-01-25Clinical Trial Update: Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma [Phase 1]
An update on a Phase 1 trial of oblimersen in combination with gemcitabine for patients with advanced solid tumors or lymphoma, which has be…
-
CLINICAL_TRIALS trial_result · 2013-01-25Clinical Trial Update: Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 2]
A Phase 2 trial evaluating interferon alfa plus thalidomide in relapsed or refractory non-Hodgkin lymphoma, specifically recurrent follicula…
-
CLINICAL_TRIALS trial_result · 2013-01-24Clinical Trial Update: Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma [Phase 1]
Phase 1 trial update for cilengitide in patients with advanced solid tumors or lymphoma, with the study status reported as completed.
-
CLINICAL_TRIALS trial_result · 2013-01-24Clinical Trial Update: Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma [Phase 1]
A Phase 1 trial evaluating genetic testing-guided irinotecan therapy in patients with solid tumors or lymphoma; the study status is complete…
-
CLINICAL_TRIALS trial_result · 2013-01-24Clinical Trial Update: Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma [Phase 1, Phase 2]
A Phase 1/Phase 2 clinical trial update evaluating oblimersen with rituximab and combination chemotherapy in relapsed or refractory aggressi…
-
CLINICAL_TRIALS trial_result · 2013-01-23Clinical Trial Update: Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 2]
A Phase 2 study evaluated oxaliplatin in patients with relapsed or refractory non-Hodgkin lymphoma across multiple subtypes and has complete…
-
CLINICAL_TRIALS trial_result · 2013-01-23Clinical Trial Update: 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma [Phase 2]
A Phase 2 trial investigating 506U78 in patients with recurrent or refractory non-Hodgkin's lymphoma and T-cell lymphomas was terminated.